Synergistic activity of Enterococcus Faeciu m-induced ferroptosis via expansion of IFN-γ+CD8+ T cell population in advanced hepatocellular carcinoma treated with sorafenib

Gut Microbes. 2024 Jan-Dec;16(1):2410474. doi: 10.1080/19490976.2024.2410474. Epub 2024 Oct 1.

Abstract

The gut microbiota plays an important role in the development and treatment of hepatocellular carcinoma (HCC). However, the implication of specific gut microbiota in targeted sorafenib therapy for advanced HCC and the microbiota mode of action, remain to be elucidated. Here, we confirmed that four bacterial genera, Lachnoclostridium, Lachnospira, Enterobacter and Enterococcus, are associated with the therapeutic efficacy of Sorafenib, and that Enterobacter faecium (Efm) plays a crucial role in modulating the sorafenib activity. The effective colonization by Emf induced the IL-12 and IFN-γ production and an increased proportion of IFN-γ+CD8+ T cells in the tumor microenvironment. Finally, exopolysaccharides (EPS) from Efm were the primary inducer to prompt IFN-γ+CD8+ T cells to secrete IFN-γ, which together with sorafenib instigated ferroptosis in HCC cells. Collectively, these results indicate that Efm is a promising probiotics that enhances the efficacy of sorafenib treatment in advanced HCC.

Keywords: Hepatocellular carcinoma; IFN-γ+CD8+ T cell; ferroptosis; gut microbiota; sorafenib.

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology
  • CD8-Positive T-Lymphocytes* / immunology
  • Carcinoma, Hepatocellular* / drug therapy
  • Carcinoma, Hepatocellular* / immunology
  • Carcinoma, Hepatocellular* / microbiology
  • Cell Line, Tumor
  • Enterococcus faecium* / drug effects
  • Ferroptosis* / drug effects
  • Gastrointestinal Microbiome / drug effects
  • Humans
  • Interferon-gamma* / immunology
  • Interferon-gamma* / metabolism
  • Liver Neoplasms* / drug therapy
  • Liver Neoplasms* / immunology
  • Liver Neoplasms* / microbiology
  • Male
  • Mice
  • Probiotics / pharmacology
  • Sorafenib* / pharmacology
  • Sorafenib* / therapeutic use
  • Tumor Microenvironment / drug effects

Substances

  • Sorafenib
  • Interferon-gamma
  • Antineoplastic Agents

Grants and funding

The work was supported by the National Natural Science Foundation of China [81703310, 81703310 and 81772628]; the National College Students Innovation Entrepreneurship Training Program [202110343054X]; the Research Foundation of National Health Commission of China- Major Medical and Health Technology Project for Zhejiang Province [WKJ-ZJ-1706]; Science and Technology Plan Project of Wenzhou Municipality [Y2020153].